A股创新药板块持续活跃，众生药业、昂利康涨停，联化科技涨超9%，睿智医药、海辰药业、翰宇药 业等高开。 订阅A股涨停捉妖队 +订阅 订阅A股市场资讯 +订阅 ...

Core Viewpoint - The recent surge in the stock price of Lianhua Technology (002250.SZ) is closely linked to the explosion at Youdao Chemical in Shandong, which is the world's largest producer of chlorantraniliprole, leading to supply disruptions and price increases in the market [1] Group 1: Stock Performance - From late May to early June, Lianhua Technology's stock price increased by 95.07%, with a weekly rise of 43.18%, closing at 11.97 yuan [1] - The stock price surge is attributed to the expected reduction in chlorantraniliprole supply due to the explosion at Youdao Chemical, which holds a 30% share of global production [1] Group 2: Business Performance - In 2024, Lianhua Technology reported a revenue of 5.677 billion yuan, a year-on-year decrease of 11.88%, while net profit attributable to shareholders increased by 122.17% to 103 million yuan, marking a return to profitability [2] - The plant protection business contributed over 60% of revenue, with a recovery in order volume and price increases for certain pesticide products [2] - The company's CDMO business is expanding, with accelerated commercialization of client validation projects [2] - The new energy business has seen breakthroughs, with products like electrolytes completing trial production, contributing to revenue growth in functional chemicals [2] Group 3: Market Dynamics - The price of K-amine has surged from approximately 130,000-150,000 yuan/ton before the explosion to 230,000-280,000 yuan/ton after the incident, with expectations that it may exceed 400,000 yuan/ton in the third quarter [2] - As the largest legal producer of K-amine globally, Lianhua Technology is positioned to potentially achieve industry exclusivity and pricing power within two years [3] Group 4: Challenges and Limitations - Despite the potential for profit increase, Lianhua Technology's production capacity utilization was only about 35% in 2023, projected to rise to 40% in 2024, limiting the ability to fully capitalize on the increased demand [3] - The company currently has a long-term contract with FMC for K-amine, restricting external sales and price flexibility until the patent expires in November 2025 [3] - The current stock price increase may be premature, as the fundamentals for K-amine are unlikely to improve significantly before November this year [4]

Market Performance - A-shares showed strong momentum with major indices rising, Shanghai Composite Index surpassed 3400 points, and ChiNext Index increased over 1% [1] - Hong Kong stocks also performed well, with the Hang Seng Index rising over 1% and returning above 24000 points, while the Hang Seng Tech Index surged nearly 3% [1] - Total market turnover reached approximately 1.31 trillion yuan, an increase of 135.5 billion yuan from the previous trading day [1] Innovative Drug Sector - The innovative drug concept stocks experienced significant gains, with the innovative drug index rising over 4% [2] - Notable stocks included Hai Chen Pharmaceutical, Rui Zhi Pharmaceutical, and others, with nearly 15 related stocks hitting the daily limit or rising over 10% [2] - Since mid-May, innovative drug stocks have shown strong performance, with some stocks like Lianhua Technology increasing nearly 115% in the last nine trading days [2] Industry Developments - The 2025 American Society of Clinical Oncology (ASCO) annual meeting highlighted the competitiveness of Chinese pharmaceutical companies in new drug development [3] - Financial policies introduced since May 7 aim to stabilize market expectations, with a focus on supporting leading pharmaceutical companies with strong dividends [3] Rare Earth Sector - The rare earth sector became active, with the rare earth permanent magnet concept index rising 3.45% [4] - The demand for medium and heavy rare earths is increasing due to the development of industries like robotics and electric vehicles [4] - Supply tightening and policy changes have led to a recovery in rare earth prices, with expectations for continued moderate price increases [5] Elderly Care Robotics - The elderly care robotics sector showed strong performance, with the humanoid robot concept index rising 0.76% [7] - The Ministry of Industry and Information Technology and the Ministry of Civil Affairs announced a pilot program for intelligent elderly care service robots from 2025 to 2027 [7] - The report emphasized the investment value of the robotics sector, highlighting various types of intelligent elderly care robots that cater to different needs [8]

Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms that the 2024 annual general meeting of shareholders for Lianhua Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][5][9]. Group 1: Meeting Procedures - The meeting was convened by the company's board of directors, and a notice detailing the time, location, agenda, voting procedures, and registration methods was published [3][4]. - The meeting took place on June 9, 2025, at 13:30 in Taizhou, Zhejiang Province, and included both on-site and online voting options [4][5]. Group 2: Attendance and Voting - A total of 405 shareholders attended the meeting, representing 911,333,117 shares, with 899,873,217 shares eligible for voting after excluding repurchased shares [5][6]. - The voting process combined both on-site and online methods, with results verified by Shenzhen Securities Information Co., Ltd. [6][9]. Group 3: Voting Results - All proposed resolutions received overwhelming support, with the following key votes: - Resolution 1: 99.7896% approval for the 2024 Board of Directors' work report [6][7]. - Resolution 5: 99.7940% approval for the 2024 profit distribution plan, with 98.2424% approval from minority shareholders [7][8]. - Resolution 9: 99.7929% approval for foreign exchange hedging business [9]. Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance qualifications, and voting procedures complied with the Company Law, Shareholders' Meeting Rules, and the company's articles of association, rendering the voting results valid [5][9].

Meeting Overview - The shareholder meeting was held in accordance with the relevant regulations and company bylaws [1][2] - A total of 2 shareholders attended the meeting in person, representing 4,721,070 shares, which is 0.5246% of the total voting shares [2] - Additionally, 403 shareholders participated via online voting, representing 271,025,997 shares, which is 31,769,074 shares or 3.5304% of the total voting shares [2] Voting Results - The resolutions were passed with a majority vote, with the following results: - For the first resolution, 270,455,734 shares voted in favor, accounting for 99.7896% of the votes [2] - For the second resolution, 270,454,234 shares voted in favor, accounting for 99.7890% of the votes [4] - For the third resolution, 270,453,234 shares voted in favor, accounting for 99.7887% of the votes [4] - For the fourth resolution, 270,467,634 shares voted in favor, accounting for 99.7940% of the votes [4] - For the fifth resolution, 243,727,017 shares voted in favor, accounting for 89.9275% of the votes [5] Shareholder Participation - Among the minority shareholders, 31,210,711 shares voted in favor of the resolutions, representing 98.2424% of the minority shareholders present [4] - The voting results indicate a strong consensus among shareholders, with minimal opposition [5]

Core Viewpoint - Company adheres to the CDMO model, aiming to provide long-term, reliable, and competitive chemical solutions to clients rather than just individual products or technologies [1] Group 1 - Company has over ten years of production history for Kamine products, indicating a strong foundation in this area [1] - A significant portion of the company's products are still under patent protection, showcasing its commitment to innovation and proprietary technology [1]

证券代码：002250 证券简称：联化科技 公告编号：2025-033 联化科技股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2025年6月9日（星期一）13时30分 2、会议地点：浙江省台州市黄岩区世纪大道3号黄岩耀达酒店会议室 3、会议召集人：联化科技股份有限公司董事会 4、会议方式：现场投票与网络投票相结合的方式 6、会议的召集、召开与表决程序符合《公司法》《上市公司股东大会规则》《深 圳证券交易所股票上市规则》等法律、法规及规范性文件和《公司章程》的规定。 （二）会议出席情况 出席现场会议的股东共2名，代表有表决权的股份数4,721,070股，占公司有表决 权股份总数的0.5246%；参加网络投票的股东共403名，代表有表决权的股份数 266,304,927股，占公司有表决权股份总数的29.5936%；参加现场与网络投票的股东 共405名，代表有表 ...

2024年度股东大会的 法律意见书 嘉源(2025)-04-413 北京市嘉源律师事务所 关于联化科技股份有限公司 2024年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 致：联化科技股份有限公司 北京市嘉源律师事务所 关于联化科技股份有限公司 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股 东大会规则》（以下简称"《股东会规则》"）等现行有效的法律、行政法规、 部门规章、规范性文件（以下简称"法律法规"）以及《联化科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，指派本所律师对公司2024 年度股东大会（以下简称"本次股东大会"）进行见证，并依法出具本法律意见 书。 为出具本法律意见书，本所指派律师见证了本次股东大会，查阅了公司提供 的与本次股东大会有关的文件和资料 ...

Group 1: Supply Chain and Market Strategy - The company is addressing supply chain risks due to the US-China trade war by gradually establishing a global supply chain and acquiring a UK base for production and delivery [1] - The company has developed potential raw material service project proposals for clients, bridging multiple supply chains [1] - The company aims to enhance its service capabilities in the pharmaceutical sector by diversifying its client base and reducing reliance on single large customers [2] Group 2: Financial Performance and Market Position - The company reports that over 50% of its revenue comes from its top five clients, indicating a strong client retention strategy [3] - The pharmaceutical segment is expected to see significant growth as more innovative drugs enter the market, which will improve the gross margin [8] - The company anticipates that the gross margin in the pharmaceutical sector will continue to rise due to a decrease in chemical raw material prices in 2024 [8] Group 3: Product Development and Innovation - The company is focusing on developing innovative agricultural products primarily for overseas clients, emphasizing efficiency and safety [6] - The company is committed to enhancing its CDMO model and expanding its product offerings in the agricultural sector [4] - The company is actively developing new additives in the lithium market, although specific products remain confidential [8] Group 4: Capacity and Production Challenges - The company acknowledges that its current production capacity and utilization rates are not optimal, but plans to improve this as business grows [12] - The company is strategically planning for future capacity expansions to meet anticipated demand [12]

Core Viewpoint - The surge in stock price of Lianhua Technology is driven by the K-amine price increase following a chemical accident, raising questions about whether this is a "value reassessment" or merely speculative trading [1][2]. Group 1: Stock Performance - Lianhua Technology's stock price doubled within 10 trading days starting from May 23, with 6 limit-up days in 8 days [1]. - On June 9, the stock closed at 14.08 yuan, marking a cumulative increase of 112.69% over the past 10 trading days [3]. Group 2: Impact of Chemical Accident - A chemical explosion at Youdao Chemical led to a significant reduction in K-amine supply, causing prices to soar from 150,000 yuan/ton to 230,000-250,000 yuan/ton [2]. - Lianhua Technology, as the largest global supplier of K-amine, benefited directly from this price surge, which catalyzed the stock price increase [2]. Group 3: Financial Performance - In 2024, Lianhua Technology achieved a net profit of 103 million yuan, a year-on-year increase of 122.17%, despite a revenue decline of 11.88% to 5.677 billion yuan [5]. - The company's pharmaceutical business, while experiencing a revenue drop of 13.32% to 1.285 billion yuan, saw a significant increase in gross margin, contributing nearly 50% of the total gross profit [5]. Group 4: Pharmaceutical Business Outlook - The pharmaceutical business primarily provides CDMO services, which do not directly involve drug development but optimize production processes for pharmaceutical companies [5]. - There are uncertainties regarding the commercialization of clinical stage projects, with a notable decline in the number of clinical III phase products compared to 2023 [6]. Group 5: CRO Business Development - To enhance customer retention, Lianhua Technology established a CRO platform in 2023, aiming to engage in early-stage drug discovery and clinical research [7]. - The CRO market in China is projected to reach 187.8 billion yuan by 2026, with a compound annual growth rate of 24.1% from 2021 to 2026 [7]. Group 6: Valuation Concerns - As of June 9, Lianhua Technology's static P/E ratio was 85.45, significantly higher than the industry averages of 33.11 for agriculture and 29.81 for pharmaceuticals [7].